Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 224

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 224
---
 reimburse each director for
reasonable and properly documented expenses incurred in performing their duties. As noted above, we also grant each director a deed of
indemnity against certain liabilities that may be incurred as a result of their service, to the extent permitted by the Companies Act.

In addition, without our prior
written consent, for a period of six months following a director’s termination from service, such director will not, whether as
a principal or agent and whether alone or jointly with, or as a director, manager, partner, shareholder, employee consultant of, any other
person, carry on or be engaged, concerned or interested in any business which is similar to or which is (or intends to be) in competition
with any business being carried on by Biodexa or any subsidiary, as applicable.

Dr. Parker Letter of Appointment

Pursuant to a term of appointment
dated June 20, 2022, or the Appointment Agreement, Dr. Parker was appointed Non-Executive Chairman of the Board of Directors, effective
as of the date thereof. The initial term of appointment for Dr. Parker expired on June 19, 2023 and was subsequently renewed for one-year.
In addition, his appointment may be terminated:

| • | by either party giving at least three months prior written notice; |

| • | by the Board of Directors reasonably determining that Dr. Parker’s acceptance of any other employment,                                   
 engagement, appointment, interest or involvement with any business or person competes or conflicts with his appointment and would result 
 in a serious conflict of interest or Dr. Parker reasonably determines such interest would result in a serious conflict of interest, and  
 Dr. Parker accepts such employment, engagement, appointment, interest or involvement;                                                    |

| • | in accordance with our articles of association or applicable law; or |

| • | he is not re-elected to the Board of Directors. |

Pursuant to the terms of the
Appointment Agreement, Dr. Parker is paid an annual fee of £82,000, plus an additional fee of £1,750 for every day in excess
of 16 days worked.

We also agreed to reimburse
Dr. Parker for reasonable and documented expenses accrued in the course of performing his duties and provide him with up to £7,500
in professional advice in connection with performing his duties. The Appointment Agreement includes provisions related to the non-disclosure
of information and assignment of inventions. Among other things, these provisions obligate Dr. Parker from disclosing any of